Skip to content

DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial

Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01745263
Acronym
DO-HEALTH
Enrollment
2157
Registered
2012-12-10
Start date
2012-12-20
Completion date
2018-01-19
Last updated
2018-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improve Healthy Ageing in Seniors; Prevent Disease at Older Age

Brief summary

The European population is aging rapidly which poses a challenge on the individual, the European societies, and health care systems. Among the most promising public health interventions that may extend healthy life expectancy at older age are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The broad aim of DO-HEALTH is to prolong healthy life expectancy in European seniors. The specific aim is to establish whether vitamin D, omega-3 fatty acids, and a simple home exercise program will prevent disease at older age. To achieve these aims, DO-HEALTH will enroll 2152 community-dwelling men and women who are 70 years and older, an age when chronic diseases increase substantially. The DO-HEALTH seniors will be recruited from 7 European cities (Zurich, Basel, Geneva, Toulouse, Berlin, Innsbruck and Coimbra) and will be randomized in a 2x2x2 factorial design trial to a simple home exercise program and/or vitamin D, and/or omega-3 fatty acids, over a 3 year period. This will allow to test the individual and the combined benefit of the interventions in the prevention of 5 primary endpoints: incident non-vertebral fractures; functional decline; systolic and diastolic blood pressure change; cognitive decline; and the rate of any infection. Key secondary endpoints include incidence of hip fractures, rate of falls, severity of pain in symptomatic knee osteoarthritis, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. All clinical endpoints will be supported by a large DO-HEALTH biomarker study to evaluate the effect of the interventions at the cellular level of multi-organ function. DO-HEALTH will further evaluate reasons why or why not seniors adhere to the 3 interventions, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease. website DO-HEALTH: http://do-health.eu/wordpress/

Detailed description

The 3 primary treatment comparisons are: 1. 2000 IU vitamin D per day compared to placebo (controlling for the other treatment strategies) 2. 1 g of omega-3 fatty acids (EPA+DHA, ratio 1:2, from marine algae) compared to placebo (controlling for the other treatment strategies) 3. Home exercise program (muscle strength) of 30 minutes 3 times a week compared to a control exercise program (joint flexibility) 30 minutes 3 times a week Follow-up: DO-HEALTH seniors will be followed for 3 years, in-person, and in 3-monthly intervals (4 clinical visits and 9 phone calls) at the 7 recruitment centers. Study population: DO-HEALTH will enroll seniors age 70 years and older. To represent the largest part of the senior population, DO-HEALTH will recruit community-dwelling seniors. However, to represent also the pre-frail population at risk of institutionalization, at least 40% of seniors will be enrolled based on a fall with or without a fracture in the year before DO-HEALTH enrolment. Study Design: This is a randomized, double-blind, placebo-controlled, 2×2×2 factorial design clinical trial. Recruitment Centers: The trial will be performed at 7 recruitment centers located in 5 countries: Switzerland (University of Zurich, Basel University Hospital, Geneva University Hospital), France (University of Toulouse Hospital Centre), Germany (Charité Berlin), Portugal (University of Coimbra), and Austria (Innsbruck Medical University). Randomization: Stratified block randomization. Labeling of study intervention will be performed by a central randomization centre in Switzerland. Stratification variables: recruitment centre (7 centers), fall during previous 12 months (yes/no), gender, and age (70 - 84 and 85+). At least 40% of Seniors among those who fell or did not fall during the last year will be enforced at each of the 7 recruitment centers. Gender and age distribution will be monitored within each recruitment centre with the DO-HEALTH randomization software. If gross imbalance (less than 30% of fallers/non-fallers in a stratum) is detected within a centre, recruitment strategies for the centre will be adapted to boost recruitment of participants of underrepresented category. website DO-HEALTH: http://do-health.eu/wordpress/

Interventions

DRUGVitamin D3

2000 IU/d

Ratio EPA:DHA = 1:2 1 g/d

PROCEDUREStrength Home Exercise
PROCEDUREFlexibility Home Exercise

Sponsors

Recruitment Partners
CollaboratorUNKNOWN
University of Geneva, Switzerland
CollaboratorOTHER
University of Basel
CollaboratorOTHER
University Hospital, Toulouse, France (Prof. Bruno Vellas, MD)
CollaboratorUNKNOWN
Charite University, Berlin, Germany
CollaboratorOTHER
Medical University Innsbruck
CollaboratorOTHER
University of Coimbra, Portugal (Prof. José daSilva, MD)
CollaboratorUNKNOWN
Other University Partners
CollaboratorUNKNOWN
University of Sheffield
CollaboratorOTHER
University of Manchester, UK (Prof. David Felson, MD MPH)
CollaboratorUNKNOWN
Max Rubner University, Germany (Prof. Bernhard Watzl, PhD)
CollaboratorUNKNOWN
Technische Universität Dresden
CollaboratorOTHER
Impact Partner
CollaboratorUNKNOWN
International Osteoporosis Foundation (IOF; Prof. John Kanis, MD)
CollaboratorUNKNOWN
SME Partners
CollaboratorUNKNOWN
Ferrari Data Solution
CollaboratorOTHER
Gut Pictures, Switzerland (Benno Gut; animated exercise video)
CollaboratorUNKNOWN
NOVAMEN, France (Sandrine Rival; logistic management partner)
CollaboratorUNKNOWN
Pharmalys, UK (Marieme Ba; monitoring partner)
CollaboratorUNKNOWN
Industry Partners
CollaboratorUNKNOWN
DSM Nutritional Products (Dr. Elisabeth Stöcklin PhD, Dr. Manfred Eggersdorfer PhD)
CollaboratorUNKNOWN
Nestlé (Michaela Höhne PhD, Irène Corthesy PhD)
CollaboratorUNKNOWN
Roche Diagnostics GmbH
CollaboratorINDUSTRY
European Commission
CollaboratorOTHER
Further collaborators and advisors at website do-health.eu
CollaboratorUNKNOWN
University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 70 years or older * Mini Mental State Examination Score of at least 24 * Living in the community * Sufficiently mobile to come to the study centre * Able to walk 10 meters with or without a walking aid and able to get in and out of a chair without help * Able to swallow study capsules * Able and willing to participate, sign informed consent (including consent to analyze all samples until drop-out or withdrawal) and cooperate with study procedures

Exclusion criteria

* Consumption of more than 1000 IU vitamin D/day in the 36 months prior to enrollment, or a bolus of 300'000 IU or more in the last 12 month prior to enrollment, and/ or unwillingness to limit vitamin D intake to the current standard of 800 IU/day of vitamin D during the course of the trial. Provision 1: an individual who consumed an average vitamin D dose between 1000 and 2000 IU vitamin D/day in the 3 months prior to enrollment, may be enrolled after a 3-month wash-out period where the maximum daily intake is limited to 800 IU vitamin D. Provision 2: an individual who consumed an average vitamin D dose higher than 2000 IU/day in the 3 months prior to enrollment, may be enrolled after a 6-month wash-out period where the maximum daily intake is limited to 800 IU vitamin D. * Unwillingness to limit calcium supplement dose to 500 mg per day for the duration of the trial * Taking omega-3 fat supplements in the 3 month prior to enrolment and unwilling to forgo their use for the duration of the trial * Use of any active vitamin D metabolite (i.e. Rocaltrol, alphacalcidiol), PTH treatment (i.e. Teriparatide), or Calcitonin at baseline and unwillingness to forego these treatments during the course of the trial * Current or recent (previous 4 months) participation in another clinical trial, or plans of such participation in the next 3 years (corresponding to DO-HEALTH length) * Presence of the following diagnosed health conditions in the last 5 years: history of cancer (except non-melanoma skin cancer); myocardial infarction, stroke, transient ischemic attack, angina pectoris, or coronary artery intervention * Severe renal impairment (creatinine clearance = 15 ml/min) or dialysis, hypercalcaemia (\> 2.6 mmol/l) * Hemiplegia or other severe gait impairment * History of hypo- or primary hyperparathyroidism * Severe liver disease * History of granulomatous diseases (i.e. tuberculosis, sarcoidosis) * Major visual or hearing impairment or other serious illness that would preclude participation * Living with a partner who is enrolled in DO-HEALTH (i.e. only one person per household can be enrolled) * Living in assisted living situations or a nursing home * Temporary exclusion: acute fracture in the last 6 weeks * Epilepsy and/or use of anti-epileptic drugs * Individuals who fell more than 3 times in the last month * Osteodystrophia deformans (M. Paget, Paget's disease) * For study centers in Germany only: persons who are institutionalized / in prison by court order (§40, Abs. 1, Art. 4, Gesetz über den Verkehr mit Arzneimitteln).

Design outcomes

Primary

MeasureTime frameDescription
Bone: Incident non-vertebral fractures over 36 monthsover 36 monthsConfirmed by medical and/or x-ray reports
Immunity: Rate of any infectionsBaseline, and every 3 months up to 36 months3-monthly incident infection protocol
Brain: Cognitive declineBaseline, 12, 24 and 36 monthsMontreal Cognitive Assessment (MoCA)
Cardio-vascular: Systolic and diastolic blood pressure changeBaseline, 12, 24 and 36 monthsStandardized blood pressure assessment in sitting position
Muscle: Functional decline (lower extremity function)Baseline, 12, 24 and 36 monthsMeasured with the SPPB (short physical performance test battery)

Secondary

MeasureTime frameDescription
Global Health: Mortality36 months
Dental: Decline in oral healthBaseline, 12,24 and 36 monthsAssessed with questionnaire.
Dental: Tooth loss36 monthsAssessed by tooth count at every clinical visit
Gastro-Intestinal: rate of GI symptomsBaseline, 12, 24 and 36 monthsAssessed with ROME III questionnaire.
Glucose-Metabolic: Change in fasting glucose, insulin levels (QUICKI, HOMA index)Baseline, 12,24,36 monthsLaboratory measures at the Central DO-HEALTH Laboratory (Institute of Clinical Chemistry at the University Hospital Zurich)
Glucose-Metabolic: Body compositionBaseline, 12, 24, 36 monthsSubset of 1502 participants with DXA measurements
Kidney: Decline in kidney functionBaseline, 12, 24, and 36 monthsBlood creatinine levels and estimated glomerular filtration rate
Global Health: Quality of lifeEvery 6 monthsAssessed with questionnaire (EuroQuol).
Global Health: Incident disability regarding activities of daily livingBaseline, 12, 24 and 36 monthsAssessed with HAQ-PROMIS questionnaire
Global Health: Incident nursing home admission36 months
Bone: Incident hip fractures36 monthsBased on medical records and/or x-ray reports
Bone: Incident total fractures36 monthsCombined non-vertebral and vertebral fractures among subgroup of 1502 participants with DXA vertebral morphometry assessment
Bone: Incident vertebral fractures36 monthsBased on DXA vertebral morphometry among subset of 1502 participants
Bone: Bone mineral density decrease at the lumbar spine and hipBaseline, 12, 24, and 36 monthsAssessed in a subset of 1502 participants with DXA measurements
Muscle: Rate of fallsAssessed every 3 months over 36 monthsAny low trauma fall, injurious fall
Muscle: reaction time and grip strengthBaseline, 12,24,36 monthsReaction time will be assessed with the repeated sit-to-stand test; grip strength will be assessed with the Martin Vigorimeter
Muscle: Muscle mass decrease at upper and lower extremitiesBaseline, 12,24,36 monthsSubset of 1502 participants with DXA measurements
Muscle: Dual tasking 10-meter gait speedBaseline, 12,24 and 36 months
Muscle/Bone: musculoskeletal painBaseline, 12,24, and 36 monthsAssessed with the McGill questionnaire
Cardio-vascular: Incident Hypertension36 months
Brain: mental health declineBaseline, 12,24, and 36 monthsAssessed with Geriatric Depression Scale
Brain: Incident Depression36 months
Brain/Muscle: Dual tasking gait variabilityBaseline, 12, 24 and 36 monthsSubset of 250 participants
Immunity: Rate of upper respiratory infections / rate of flu-like illness36 monthsAssessed with infection protocol every 3 months
Immunity: Incident severe infections that lead to hospital admission36 months
Cartilage/Bone: Severity of knee pain in participants with symptomatic knee osteoarthritisBaseline, 12, 24 and 36 monthsAssessed with the KOOS questionnaire. Knee OA assessment with modified ACR criteria.
Cartilage/Bone: Rate of knee bucklingBaseline, 12,24,36 monthsQuestionnaire-based.
Cartilage/Bone: NSAID use / number of joints with painBaseline, 12, 24, 36 monthsAssessed by questionnaire and homunculus figure

Other

MeasureTime frameDescription
Immunity: Incident cancer / rate of implant infections / rate of gastro-intestinal infections36 monthsIncident cancer (any cancer, gastro-intestinal, breast cancer in women, prostate cancer in men); rate of implant infections after total hip or knee replacement (due to fracture or osteoarthritis); rate of gastro-intestinal infections
Cartilage/bone: Incident osteoarthritisBaseline, 12, 24, and 36 monthsIncident symptomatic knee osteoarthritis; incident symptomatic hip osteoarthritis, incident symptomatic hand osteoarthritis; composite endpoint: incident symptomatic knee, hip or hand osteoarthritis; severity of hip pain in those with prevalent symptomatic hip osteoarthritis, severity of hand pain in those with prevalent symptomatic hand osteoarthritis
Adherence laboratoryBaseline, 12, 24, and 36 monthsSerum 25(OH)D concentrations (measured both by an automated assay and HPLCMS/MS) and plasma PUFA concentrations (EPA, AA, DPA, DHA; measured by a sensitive and selective assay based on gas chromatography coupled to mass spectrometry detection (GC-MS)) in all participants
Muscle: Incident sarcopenia / incident frailty / decline in physical function36 monthsIncident sarcopenia (among subset of 1502 seniors with yearly DXA measurements), incident frailty (questionnaire), decline in physical activity (questionnaire)
BONE: Functional recovery after long bone fracture36 months
Bone: Incident repeat fractures36 monthsAny repeat non-vertebral fractures in all participants, vertebral fractures and total fractures among subset of 1502 seniors with yearly DXA measurements
Biomarker endpointsBaseline, 12, 24, and 36 months
Brain: incident dementia36 months
Cardio-vascular: Major cardio-vascular events36 monthsMajor cardiovascular events as a composite endpoint (any event: myocardial infarction, stroke, revascularization procedures of CABG and PCI, incident congestive heart disease, cardiovascular mortality); individual endpoints: myocardial infarction, stroke, incident congestive heart disease, and cardiovascular mortality (assessed every 3 months over 36 months)

Countries

Austria, France, Germany, Portugal, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026